A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions

A necessary and useful approach

H. J. Park, J. H. Lee, S. R. Kim, S. H. Kim, K. H. Park, C. K. Lee, B. D. Kang, S. H. Beom, S. J. Shin, M. Jung, Jungwon Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect against these reactions and to validate a new practical desensitization protocol. Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags. Results: Of the 271 patients administered oxaliplatin, 45 (16.6%) experienced IHSRs. Of 39 patients who experienced an IHSR but needed to continue oxaliplatin, 6 (15.4%) stopped treatment due to the reaction, and 33 (84.6%) continued despite the risk of further reactions. The new desensitization protocol was successfully completed in 12 patients (100%), but it was ineffective in 3 patients (all with a negative skin prick test), who experienced fever without urticaria. Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.

Original languageEnglish
Pages (from-to)168-176
Number of pages9
JournalJournal of Investigational Allergology and Clinical Immunology
Volume26
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

oxaliplatin
Immediate Hypersensitivity
Drug Therapy
Urticaria
Skin Tests
Platinum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Park, H. J. ; Lee, J. H. ; Kim, S. R. ; Kim, S. H. ; Park, K. H. ; Lee, C. K. ; Kang, B. D. ; Beom, S. H. ; Shin, S. J. ; Jung, M. ; Park, Jungwon. / A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions : A necessary and useful approach. In: Journal of Investigational Allergology and Clinical Immunology. 2016 ; Vol. 26, No. 3. pp. 168-176.
@article{bc88ab9f2e2d42a7ad0cb5ad375e9a7c,
title = "A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions: A necessary and useful approach",
abstract = "Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect against these reactions and to validate a new practical desensitization protocol. Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags. Results: Of the 271 patients administered oxaliplatin, 45 (16.6{\%}) experienced IHSRs. Of 39 patients who experienced an IHSR but needed to continue oxaliplatin, 6 (15.4{\%}) stopped treatment due to the reaction, and 33 (84.6{\%}) continued despite the risk of further reactions. The new desensitization protocol was successfully completed in 12 patients (100{\%}), but it was ineffective in 3 patients (all with a negative skin prick test), who experienced fever without urticaria. Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.",
author = "Park, {H. J.} and Lee, {J. H.} and Kim, {S. R.} and Kim, {S. H.} and Park, {K. H.} and Lee, {C. K.} and Kang, {B. D.} and Beom, {S. H.} and Shin, {S. J.} and M. Jung and Jungwon Park",
year = "2016",
month = "1",
day = "1",
doi = "10.18176/jiaci.0038",
language = "English",
volume = "26",
pages = "168--176",
journal = "Journal of Investigational Allergology and Clinical Immunology",
issn = "1018-9068",
publisher = "Esmon",
number = "3",

}

A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions : A necessary and useful approach. / Park, H. J.; Lee, J. H.; Kim, S. R.; Kim, S. H.; Park, K. H.; Lee, C. K.; Kang, B. D.; Beom, S. H.; Shin, S. J.; Jung, M.; Park, Jungwon.

In: Journal of Investigational Allergology and Clinical Immunology, Vol. 26, No. 3, 01.01.2016, p. 168-176.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions

T2 - A necessary and useful approach

AU - Park, H. J.

AU - Lee, J. H.

AU - Kim, S. R.

AU - Kim, S. H.

AU - Park, K. H.

AU - Lee, C. K.

AU - Kang, B. D.

AU - Beom, S. H.

AU - Shin, S. J.

AU - Jung, M.

AU - Park, Jungwon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect against these reactions and to validate a new practical desensitization protocol. Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags. Results: Of the 271 patients administered oxaliplatin, 45 (16.6%) experienced IHSRs. Of 39 patients who experienced an IHSR but needed to continue oxaliplatin, 6 (15.4%) stopped treatment due to the reaction, and 33 (84.6%) continued despite the risk of further reactions. The new desensitization protocol was successfully completed in 12 patients (100%), but it was ineffective in 3 patients (all with a negative skin prick test), who experienced fever without urticaria. Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.

AB - Background and Objective: Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures to protect against these reactions and to validate a new practical desensitization protocol. Methods: We retrospectively reviewed 2640 cases of oxaliplatin IHSRs in 271 oxaliplatin users and prospectively used a newly designed desensitization protocol 32 times in 12 patients with hypersensitivity to platinum-based chemotherapy. The protocol consisted of increases in infusion rate every 15 minutes, regardless of the concentration of the chemotherapy agent in the infusion bags. Results: Of the 271 patients administered oxaliplatin, 45 (16.6%) experienced IHSRs. Of 39 patients who experienced an IHSR but needed to continue oxaliplatin, 6 (15.4%) stopped treatment due to the reaction, and 33 (84.6%) continued despite the risk of further reactions. The new desensitization protocol was successfully completed in 12 patients (100%), but it was ineffective in 3 patients (all with a negative skin prick test), who experienced fever without urticaria. Conclusions: Many patients who experience oxaliplatin-induced IHSRs are required to stop first-line oxaliplatin-based chemotherapy or to continue without desensitization, with the associated risks. Our new desensitization protocol is practical and easy to use in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84975037789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975037789&partnerID=8YFLogxK

U2 - 10.18176/jiaci.0038

DO - 10.18176/jiaci.0038

M3 - Article

VL - 26

SP - 168

EP - 176

JO - Journal of Investigational Allergology and Clinical Immunology

JF - Journal of Investigational Allergology and Clinical Immunology

SN - 1018-9068

IS - 3

ER -